The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States
Open accessAbstract
Importance: Although the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been thought to have increased during the past decades, updated epidemiologic and survival data are lacking. Objectives: To conduct an epidemiologic and survival analysis of the largest cohort of patients with GEP-NETs using the latest data and to establish a novel nomogram to predict the survival probability of individual patients with GEP-NETs. Design, Setting, and Participants: In this cohort study, 43 751 patients with GEP-NETs diagnosed from January 1, 1975, to December 31, 2015, were identified from the Surveillance, Epidemiology, and End Results Program. Associated data were used for epidemiologic and survival analysis, as well as the establishment and validation of a nomogram to predict the survival probability of individual patients with GEP-NETs. The study cutoff date was December 31, 2018. Statistical analysis was performed from February 1 to April 30, 2020. Main Outcomes and Measures: Incidence, factors associated with overall survival, and a nomogram model for patients with GEP-NETs. Results: A total of 43 751 patients received a diagnosis of GEP-NETs from 1975 to 2015 (22 398 women [51.2%], 31 976 White patients [73.1%], 7097 Black patients [16.2%], 3207 Asian and Pacific Islander patients [7.3%], 270 American Indian and Alaska Native patients [0.6%], and 4546 patients of unknown race [10.4%]; mean [SD] age at diagnosis, 58 [15] years). The age-adjusted incidence rate of GEP-NETs increased 6.4-fold from 1975 to 2015 (annual percentage change [APC], 4.98; 95% CI, 4.75-5.20; P < .001). Furthermore, among site groups, the incidence of GEP-NETs in the rectum increased most significantly (APC, 6.43; 95% CI, 5.65-7.23; P < .001). As for stage and grade, the incidence increased the most in localized GEP-NETs (APC, 6.53; 95% CI, 6.08-6.97; P < .001) and G1 GEP-NETs (APC, 18.93; 95% CI, 17.44-20.43; P < .001). During the study period, the mean age at diagnosis for localized disease increased by 9.0 years (95% CI, 3.3-14.7 years; P = .002), which remained unchanged for regional and distant cases. On multivariable analyses, age, sex, marital status, and tumor size, grade, stage, and site were significantly associated with overall survival for patients with GEP-NETs (eg, patients with distant vs localized disease: hazard ratio, 10.32; 95% CI, 8.56-12.43; G4 vs G1 GEP-NET: hazard ratio, 6.37; 95% CI, 5.39-7.53). Furthermore, a nomogram comprising age, size, grade, stage, and site was established to predict the 3-year and 5-year survival probability, with the concordance indexes of 0.893 (95% CI, 0.883-0.903) for the internal validations and 0.880 (95% CI, 0.866-0.894) for the external validations. The receiver operating characteristic curve demonstrated that the nomogram exhibited better discrimination power than TNM classification (area under the curve for 3-year overall survival, 0.908 vs 0.795; for 5-year overall survival, 0.893 vs 0.791). Conclusions and Relevance: In this study, the incidence and prevalence of GEP-NETs have continued to increase over 40 years, especially among patients with rectal GEP-NETs. In addition, this study suggests that a nomogram with 5 prognostic parameters may accurately quantify the risk of death among patients with GEP-NETs, indicating that it has satisfactory clinical practicality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,256
Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Klimstra, D. S., Modlin, I. R., Coppola, D., Lloyd, R. V., & Suster, S. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ec124e · Cited by 1,072
Hallet, J., Law, C. H. L., Cukier, M., Saskin, R., Liu, N., & Singh, S. (2015) · Cancer · doi:10.1002/cncr.29099 · Cited by 852
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Neuroendocrine tumor epidemiology: Contrasting Norway and North America
Hauso, O., Gustafsson, B. I., Kidd, M., Waldum, H. L., Drozdov, I., Chan, A. K. C., & Modlin, I. M. (2008) · Cancer · doi:10.1002/cncr.23883 · Cited by 505
Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Díaz-Pérez, J. A., Martínez del Prado, M. P., Alonso Orduña, V., Sevilla-García, I., Villabona-Artero, C., Beguiristain-Gómez, A., Llanos-Muñoz, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq022 · Cited by 419
Shariat, S. F., Karakiewicz, P. I., Suardi, N., & Kattan, M. W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4713 · Cited by 288
Korse, C. M., Taal, B. G., van Velthuysen, M.-L. F., & Visser, O. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.022 · Cited by 239
Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
Mafficini, A., & Scarpa, A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00160 · Cited by 215
Chen, D., Liu, Z., Liu, W., Fu, M., Jiang, W., Xu, S., Wang, G., Chen, F., Lu, J., Chen, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20429-0 · Cited by 180
Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015
Scott, A. R., Stoltzfus, K. C., Tchelebi, L. T., Trifiletti, D. M., Lehrer, E. J., Rao, P., Bleyer, A., & Zaorsky, N. G. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.27738 · Cited by 173
Berardi, G., Morise, Z., Sposito, C., Igarashi, K., Panetta, V., Simonelli, I., Kim, S., Goh, B. K. P., Kubo, S., Tanaka, S., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.032 · Cited by 160
Thomas, D., Tsolakis, A. V., Grozinsky‐Glasberg, S., Fraenkel, M., Alexandraki, K., Sougioultzis, S., Gross, D. J., & Kaltsas, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0836 · Cited by 105
The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines
Zandee, W. T., & de Herder, W. W. (2018) · Neuroendocrinology · doi:10.1159/000486096 · Cited by 95
Survival and prognostic factors in patients with small bowel carcinoid tumour
Landerholm, K., Zar, N., Andersson, R. E., Falkmer, S. E., & Järhult, J. (2011) · British journal of surgery · doi:10.1002/bjs.7649 · Cited by 80
Zhang, W., Wang, W., Han, X., Gao, H.-L., Xu, S., Li, S., Li, T., Xu, H., Li, H., Ye, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001188 · Cited by 61
Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer
Sigal, D. S., Tartar, M., Xavier, M. F., Bao, F., Foley, P. J., Luo, D., Christiansen, J., Hornby, Z., Maneval, E. C., & Multani, P. S. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7029 · Cited by 39
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., Pellè, E., & Strosberg, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113655 · Cited by 37
The Clinical Features and Molecular Mechanisms of ACTH-secreting Pancreatic Neuroendocrine Tumors
Zhang, C., Jin, J., Xie, J., Ye, L., Su, T., Jiang, L., Zhou, W., Jiang, Y., Wu, L., Wang, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa507 · Cited by 36
Tian, F., Cai, Y., Zhuang, L.-P., Ming-fang, C., Xiu, Z., Zhang, Y., Liu, H., Liu, Z., Liu, G., Zeng, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1683 · Cited by 12
Liu, Q., & Polydorides, A. D. (2020) · Modern Pathology · doi:10.1038/s41379-020-0585-1 · Cited by 11
Causes of Death After Neuroendocrine Tumors Diagnosis
Sonbol, M. B., Saad, A. M., González-Vélez, M., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001723 · Cited by 8
Cited by
Yang, K., Li, J., Cheng, Y., & Bai, C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0441 · Cited by 4
Metadata
- Authors
- Xu, Z., Wang, L., Dai, S., Chen, M., Li, F., Sun, J., & Luo, F.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-23
- Volume
- 4
- Issue
- 9
- Pages
- e2124750
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W3201005809
- Cited by
- 264
- References
- 26
- FWCI
- 23.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.